OBJECTIVES: The objective of this budget impact analysis is to estimate the impact of insulin Glargine-300U/mL (Gla-300)introduction in Algeria, in targeted and eligible population, over a time horizon of 5 years, from the Algerian health care system's perspective, including treatment costs, administration costs, glycemic monitoring costs and direct costs related to the management of severe hypoglycemia

METHODS: The budget impact analysis was designed with a 5-years time horizon for patients with T1DM and T2DM, epidemiology data references were from National office of statistics, Stepwise WHO and IDMPS wave 7, the eligible population considered was: (T1DM new patients, T1DM uncontrolled patients with HBA1C>9%, insulin naïve, uncontrolled T2DM patients using OAD with HBA1C >7%, uncontrolled T2DM patients using insulin with HBA1C>9%). The costs included are treatment costs, costs of glycemic self-monitoring which are covered by the health insurance (CNAS or CASNOS), administration costs, direct costs related to the management of severe hypoglycemia (glycemic control costs + assistance costs, transport, healthcare utilization). All costs were reported in Algerian dinars (AD). Deterministic sensitivity analysis was carried out on all relevant costs and parameters included in the budget impact assessment

RESULTS: The results showed a negative budget of (BI = -643M AD) cumulative over the 5 years. The breakdown of the budget impact per population is: -342M AD for T1DM, -42M AD for insulin naive patients and -247 M AD for T2DM uncontrolled patients using insulin. Sensitivity analyses determined that the cost of insulin Glargine-300U/mL (Gla-300) and eligible population had the potential to impact the base case analysis

CONCLUSIONS: The total budget for the introduction of insulin Glargine-300U/mL (Gla-300)in Algeria has a considerable saving on health expenses and on the social security budget (-643M AD over 5 years).Hence insulin Glargine-300U/mL (Gla-300)as an innovative 2nd Generation basal insulin is characterized with beneficial clinical and economic value